Salute e Benessere
BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
Before joining Sanofi Pasteur-Canada in 1999, Dr. Tartaglia was Executive Director of Research at Virogenetics Corporation of Troy, New York , a former subsidiary of Sanofi Pasteur. At Virogenetics he helped develop the poxvirus vector technology as an immunization vehicle for both veterinary and human application, including HIV and cancer. Prior to joining Virogenetics in 1990, Jim worked as a research scientist with the New York State Department of Health and was a postdoctoral fellow at the Roche Institute of Molecular Biology in Nutley, New Jersey . He holds a PhD from the Department of Microbiology and Immunology at Albany Medical College and a BSc in biology from Bucknell University in Lewisburg, Pennsylvania. Jim is an inventor on over 20 patents relating to recombinant vaccines and has authored over 130 publications in the areas of molecular virology and recombinant vaccine technology and participates as associate editor and/or reviewer for several peer-reviewed journals.
BioVaxys President and Chief Operating Officer Kenneth Kovan stated, says "We are very excited to have the support of Dr. Tartaglia on the BioVaxys board. We are looking forward to tapping into his expertise as we prioritize DPX-based vaccine programs for fields of significant unmet need and build collaborations with global vaccine companies based on the DPX platform."
BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.
BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at www.sedar.com.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
Logo - https://mma.prnewswire.com/media/1430981/5551621/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-appoints-former-sanofi-vaccines-executive-to-board-of-directors-302578255.html